Mirae Asset Global Investments Co. Ltd. Has $71,000 Stock Position in Disc Medicine, Inc. $IRON

Mirae Asset Global Investments Co. Ltd. increased its position in Disc Medicine, Inc. (NASDAQ:IRON) by 15.6% in the second quarter, Holdings Channel.com reports. The firm owned 1,338 shares of the company’s stock after acquiring an additional 181 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Disc Medicine were worth $71,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Amalgamated Bank increased its position in Disc Medicine by 38.6% in the first quarter. Amalgamated Bank now owns 787 shares of the company’s stock worth $39,000 after purchasing an additional 219 shares during the period. Caitong International Asset Management Co. Ltd increased its position in Disc Medicine by 13,428.6% in the first quarter. Caitong International Asset Management Co. Ltd now owns 947 shares of the company’s stock worth $47,000 after purchasing an additional 940 shares during the period. Avanza Fonder AB acquired a new position in shares of Disc Medicine during the 2nd quarter worth about $57,000. Arizona State Retirement System grew its position in shares of Disc Medicine by 12.5% during the 1st quarter. Arizona State Retirement System now owns 5,315 shares of the company’s stock worth $264,000 after buying an additional 590 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Disc Medicine during the 1st quarter worth about $317,000. 83.70% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on IRON. HC Wainwright restated a “buy” rating and set a $118.00 target price on shares of Disc Medicine in a research report on Thursday, July 3rd. Truist Financial began coverage on Disc Medicine in a research report on Monday, July 21st. They set a “buy” rating and a $86.00 target price for the company. Morgan Stanley boosted their target price on Disc Medicine from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Monday, August 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Disc Medicine in a research report on Wednesday, October 8th. Finally, Wedbush restated an “outperform” rating and set a $90.00 target price on shares of Disc Medicine in a research report on Monday, July 21st. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Disc Medicine currently has a consensus rating of “Moderate Buy” and an average price target of $98.30.

Disc Medicine Trading Down 1.2%

NASDAQ:IRON opened at $69.90 on Monday. Disc Medicine, Inc. has a fifty-two week low of $30.82 and a fifty-two week high of $72.68. The company has a debt-to-equity ratio of 0.05, a current ratio of 32.11 and a quick ratio of 32.11. The stock has a market capitalization of $2.43 billion, a PE ratio of -15.64 and a beta of 0.80. The business’s 50-day simple moving average is $61.86 and its 200-day simple moving average is $53.83.

Disc Medicine (NASDAQ:IRON) last released its quarterly earnings data on Thursday, August 7th. The company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.41). Sell-side analysts expect that Disc Medicine, Inc. will post -4.07 earnings per share for the current fiscal year.

Insider Activity

In other Disc Medicine news, CFO Jean M. Franchi sold 2,031 shares of the business’s stock in a transaction that occurred on Thursday, July 17th. The stock was sold at an average price of $59.00, for a total value of $119,829.00. Following the sale, the chief financial officer owned 63,499 shares in the company, valued at approximately $3,746,441. The trade was a 3.10% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Kevin Bitterman sold 71,961 shares of the business’s stock in a transaction that occurred on Wednesday, October 8th. The shares were sold at an average price of $70.58, for a total value of $5,079,007.38. Following the completion of the sale, the director owned 500,621 shares in the company, valued at $35,333,830.18. The trade was a 12.57% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 178,913 shares of company stock worth $11,737,613 in the last quarter. 3.64% of the stock is currently owned by company insiders.

Disc Medicine Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.